The path less costly.

In this article the author comments on the cases of Genzyme and Genentech, two U.S. biotechnology companies that took opposite approaches when faced with a competitive threat. He discusses the effort made by Genzyme to acquire competitor Novazyme Pharmaceuticals when the company was in financial trouble. He also examines the competition between Genentech and Tanox over an anti-immunoglobulin solution.